Key points are not available for this paper at this time.
Radiolabeled somatostatin subtype 2 receptor (SST2R)-antagonists have shown advantageous profiles for cancer theranostics compared with agonists. On the other hand, the newly introduced hybrid chelator (6-pentanoic acid)-6-(amino)methyl-1,4-diazepinetriacetate (DATA5m) rapidly binds Ga-68 (t1/2: 67.7 min) at much lower temperature, thus allowing for quick access to “ready-for-injection” 68GaGa-tracers in hospitals. We herein introduce 68GaGa-DATA5m-LM4 for PET/CT imaging of SST2R-positive human tumors. LM4 was obtained by 4Pal3/Tyr3-substitution in the known SST2R antagonist LM3 (H-DPhe-cDCys-Tyr-DAph(Cbm)-Lys-Thr-Cys-DTyr-NH2) and DATA5m was coupled at the N-terminus for labeling with radiogallium (Ga-67/68). 67GaGa-DATA5m-LM4 was evaluated in HEK293-SST2R cells and mice models in a head-to-head comparison with 67GaGa-DOTA-LM3. Clinical grade 68GaGa-DATA5m-LM4 was prepared and injected in a neuroendocrine tumor (NET) patient for PET/CT imaging. DATA5m-LM4 displayed high SST2R binding affinity. 67GaGa-DATA5m-LM4 showed markedly higher uptake in HEK293-SST2R cells versus 67GaGa-DOTA-LM3 and was stable in vivo. In HEK293-SST2R xenograft-bearing mice, it achieved longer tumor retention and less kidney uptake than 67GaGa-DOTA-LM3. 68GaGa-DATA5m-LM4 accurately visualized tumor lesions with high contrast on PET/CT. In short, 68GaGa-DATA5m-LM4 has shown excellent prospects for the PET/CT diagnosis of SST2R-positive tumors, further highlighting the benefits of Ga-68 labeling in a hospital environment via the DATA5m-chelator route.
Kanellopoulos et al. (2022) studied this question.